New cure within reach for Victorians with hepatitis C

New cure within reach for Victorians with hepatitis C

The Pharmaceutical Benefits Advisory Committee(PBAC) has this afternoon made a recommendation to subsidise a new form of antiviral medicine on the Pharmaceutical Benefits Scheme (PBS) for the treatment of chronic hepatitis C.

Click here to view the recommendations made by the PBAC

08 April 2015

 

Approximately 60% of newly acquired hepatitis C infections occur in young people aged 15-29. Preventing hepatitis transmissions in young people is not as simple as telling people ‘don’t share a bloody thing’.

SKiNK will be a...

08 April 2015

Following consideration at its March meeting the Pharmaceutical Benefits Advisory Committee (PBAC) announced on Friday 24 April its recommendation for new hep C treatment drugs Sofosbuvir; Sofosbuvir/ledipasvir; and, Daclatasvir/sofosbuvir to be listed on the PBS. The positive...

Latest news stories

26 April 2015

Hepatitis Victoria has welcomed today’s announcement by the Pharmaceutical Benefits Advisory Committee(PBAC) of its recommendation that a new form of antiviral medicine for the treatment of chronic hepatitis C (...

29 March 2015

Hepatitis Victoria's Street Shot program was introduced to a number of young people in...